Research implementation status
In sub-theme I, we obtained important results towards realization of the early cancer diagnosis device such as improvement to the sensitivity of the electric potential measurement and the fluorescence measurement methods for microRNA (miRNA), and establishment of the integration technology of the body fluid preprocessing element and the detection element. In addition, we developed single particle analysis technique and succeeded in identifying exosome derived from cancer cell from blood sample of tumor-bearing mice, which lead to highly precision analysis of miRNA.
In sub-theme II, we developed a Mn-containing calcium phosphate micelle responding to the low pH environment of cancer for MRI diagnoses, and succeeded in depicting the minute liver metastasis of cancer by MRI. About anticancer agent and the siRNA-containing nano devices, we succeeded in the targeted treatment of the autogenesis model of the pancreatic cancer. In addition, we substantiated the effectiveness of the peptide ligand mounted micelle for intractable brain tumor in vivo, and the new findings including the toxicity reduction effect by the promotion of the choler excretion was confirmed. Furthermore, regarding thr development to clinical practice, paclitaxel-containing micelle advanced to the Phase III, that is the final stage of the clinical trials, and the route towards the approval as a drug was clarified. Furthermore, on the hollow model nano device, we substantiated the activity of the delivery enzyme in local spot of solid cancer and confirmed its usefulness as the enzyme prodrug therapy.
In sub-theme III, we carried out photodynamics treatment (PDT) of the solid cancer with a photosensitizer mounted nano device to clarify its effectiveness, and using a bladder cancer orthotopic transplantation rat model, we disclosed the effectiveness of combination with the homogeneous light irradiation system. Furthermore, as for apparatus development, we developed a navigation system of the light and the supersonic wave, and optimized the supersonic wave irradiation conditions for SDT.
In sub-theme IV, we selected the candidates for bioactive substances in tissue reconstruction and validated them using animal models, and confirmed the effective controlled release of the bioactive substances for implant device for tissue reconstruction. Meanwhile, as for the implant for soft tissue deficiencies, we started considering its effectiveness using a nucleus pulposus deficient rabbit model.